1-2 of 2
Akihiro Bessho
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630

Yuri Taniguchi, Tsuneo Shimokawa, Yuichi Takiguchi, Toshihiro Misumi, Yukiko Nakamura, Yosuke Kawashima, Naoki Furuya, Yoshimasa Shiraishi, Toshiyuki Harada, Hisashi Tanaka, Satoru Miura, Ayumi Uchiyama, Yoshiro Nakahara, Takaaki Tokito, Katsuhiko Naoki, Akihiro Bessho, Yasuhiro Goto, Masahiro Seike, Hiroaki Okamoto
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4402–4409.
https://doi.org/10.1158/1078-0432.CCR-22-1687
Published: 14 October 2022
View article titled, A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
Open the PDF for A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630 in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Daichi Fujimoto, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Junko Tanizaki, Koichi Azuma, Shota Omori, Motoko Tachihara, Kazumi Nishino, Akihiro Bessho, Yasutaka Chiba, Koji Haratani, Kazuko Sakai, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 893–902.
https://doi.org/10.1158/1078-0432.CCR-21-3194
Published: 01 March 2022
View article titled, A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for <em>EGFR</em>-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Open the PDF for A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for <em>EGFR</em>-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) in another window
Includes: Supplementary data